Apnimed
  • About
    • Apnimed Team
    • Board of Directors
    • Scientific Advisory Board
  • Obstructive Sleep Apnea
  • Our Science
  • Pipeline
  • News
    • Events
  • Careers
  • Contact Us
Select Page

Apnimed Strengthens Management Team with Addition of Leading Sleep Medicine Expert, David P. White, M.D.

Mar 4, 2021 | 2021

– Dr. White joins Apnimed as Distinguished Scientist and Chair of the company’s Scientific Advisory Board – – Additionally, Luigi Taranto Montemurro, M.D., promoted to Chief Scientific Officer – CAMBRIDGE, Mass. March 04, 2021 – Apnimed, a clinical-stage company...

Apnimed Announces First Patient Dosed in a Second Phase 2 Clinical Trial with AD109, a Disease Modifying Candidate for Obstructive Sleep Apnea

Jan 19, 2021 | 2021

– Data from this study in patients with mild to moderate disease anticipated the 2nd quarter – – Data from the first Phase 2 study investigating AD109 in patients with a broad spectrum of disease severity also anticipated in 2ndquarter –  – Phase 3 registrational...

News

  • 2020
  • 2021
  • Events
  • About
  • Obstructive Sleep Apnea
  • Our Science
  • Pipeline
  • News
  • Careers
  • Contact Us
  • Twitter
  • Google

Privacy Policy | Terms and Conditions

©2021 Apnimed. All rights reserved. Apnimed is a Cambridge, MA-based clinical-stage company dedicated to the discovery of novel therapies for sleep apnea and related disorders. The characterization of the discovery and development efforts on this website, as well as the expectations associated with them, are reflective of the current state of development and may change as the Company progresses.